Posted by Michael Wonder on 12 Sep 2023
Affimed receives FDA fast track designation for AFM13 in combination with AlloNK for the treatment of patients with relapsed or refractory Hodgkin lymphoma
12 September 2023 - Affimed today announced that the FDA has granted fast track designation to the combination of its innate cell engager AFM13 with AlloNK for the potential treatment of relapsed/refractory Hodgkin lymphoma.
The combination treatment is entering Phase 2 development and will be investigated in Affimed’s LuminICE-203 study, which received IND clearance earlier this year; the study also includes an exploratory cohort of CD30 positive peripheral T-cell lymphoma patients.
